Pancreatitis News and Research

RSS

Pancreatitis is inflammation of the pancreas. The pancreas is a large gland behind the stomach and close to the duodenum—the first part of the small intestine. The pancreas secretes digestive juices, or enzymes, into the duodenum through a tube called the pancreatic duct. Pancreatic enzymes join with bile—a liquid produced in the liver and stored in the gallbladder—to digest food. The pancreas also releases the hormones insulin and glucagon into the bloodstream. These hormones help the body regulate the glucose it takes from food for energy.

Normally, digestive enzymes secreted by the pancreas do not become active until they reach the small intestine. But when the pancreas is inflamed, the enzymes inside it attack and damage the tissues that produce them.

Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. In severe cases, bleeding, infection, and permanent tissue damage may occur.

Merck's GARDASIL receives approval from FDA Advisory Committee

Merck & Co., Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.

10 Sep 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.

20 Aug 2009

Amsterdam Molecular Therapeutics reports 2009 half year financials

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2009.

13 Aug 2009

Study could help target new pancreatitis treatments

Pancreatitis is often a fatal condition, in which the pancreas digests itself and surrounding tissue. Scientists have previously found that alcohol can trigger the condition by combining with fatty acids in the pancreas, which leads to an excessive release of stored calcium ions. Once calcium ions enter cell fluid in the pancreas it activates digestive enzymes and damages the cells.

29 Jun 2009

Early detection of pancreatic cancer closer thanks to multifunctional nanoparticles

Pancreatic cancer has a devastatingly low survival rate (less than 5 percent after 5 years) because it is usually diagnosed at an advanced stage. The initial symptoms, such as pain, jaundice, or weight loss, often do not allow the disease to be caught early enough for surgery and chemotherapy to be effective.

28 Jun 2009

Study redefines alcohol and smoking’s role in pancreatitis

Although alcohol consumption is known to be associated with chronic pancreatitis, new evidence indicates that a threshold of five or more drinks per day is required to significantly raise risk; however, most patients with chronic pancreatitis do not drink this amount, according to a report in the June 8 issue of Archives of Internal Medicine. In addition, smoking is an independent, dose-dependent risk factor.

9 Jun 2009

Toddler’s mysterious meningitis trumps cancer threat

Brooklynn Spencer's mother Samantha knew something wasn't right. The 8 month old had the flu recently, but it had been four weeks. She should have been better. The Elmira mother of four pushed for blood tests in early October 2007. A few hours later, there was a knock at the door.

21 May 2009

Amsterdam Molecular Therapeutics commences preregistration trial for Glybera

Amsterdam Molecular Therapeutics announced today the treatment of the first patient in a preregistration clinical trial with Glybera. This gene therapy product targets lipoprotein lipase deficiency (LPLD), a seriously debilitating and potentially lethal disease.

7 May 2009

Study examines radiation dose estimates for pregnant women undergoing therapeutic ERCP

Pregnant women with gallstone disease may require immediate endoscopic intervention because of potentially life-threatening cholangitis (infection in the bile ducts) or gallstone pancreatitis (inflammation of the pancreas).

30 Apr 2009

Thymoquinone inhibits the development of pancreatic cancer

An herb recently found to kill pancreatic cancer cells also appears to inhibit development of pancreatic cancer as a result of its anti-inflammatory properties, according to researchers from the Kimmel Cancer Center at Jefferson.

20 Apr 2009

Two or more alcoholic drinks a day may increase pancreatic cancer risk

Men and women who consume two or more alcoholic drinks a day could increase their risk of developing pancreatic cancer, according to a study published in Cancer Epidemiology, Biomarkers and Prevention , a journal of the American Association for Cancer Research.

2 Apr 2009

Smoking linked to greater risk for pancreatitis

Smoking appears to be associated with an increased risk of acute and chronic pancreatitis, according to a report in the March 23 issue of Archives of Internal Medicine.

23 Mar 2009

High triglyceride levels common, often untreated among Americans

High concentrations of blood fats known as triglycerides are common in the United States, according to a report in the March 23 issue of Archives of Internal Medicine.

23 Mar 2009

A tipple a day may increase pancreatic cancer risk

3 Mar 2009

Discovery of gene involved in pancreatic cancer

Researchers from the University of Michigan Comprehensive Cancer Center have identified a gene that is overexpressed in 90 percent of pancreatic cancers, the most deadly type of cancer.

2 Mar 2009

Costs of digestive diseases grown to more than $141 billion a year

Digestive, liver and pancreatic diseases result in more than 100 million outpatient visits and 13 million hospitalizations annually at a cost of $141.8 billion.

10 Feb 2009

Top hospitals have 27 percent lower mortality: Annual HealthGrades study

Medicare patients treated at top-rated hospitals nationwide across the most common Medicare diagnoses and procedures are 27 percent less likely to die, on average, than those admitted to all other hospitals, according to a study released today by HealthGrades, the leading independent healthcare ratings organization.

29 Jan 2009